Lupin gains EIR from US FDA for its Somerset manufacturing facility
The facility was inspected from May 7 to May 17, 2024
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Lupin
Lupin appoints Abdelaziz Toumi as CEO of its API CDMO subsidiary
Holding a Doctorate in chemical engineering, Abdel, brings over two decades of experience in the biotech, pharma and CDMO sectors…
Lupin announces closure of US FDA inspection
The inspection was conducted at its injectables facility in Nagpur
Lupin, Fuji sign agreement to commercialise Nextstellis in Vietnam, Philippines
Lupin, Fuji sign agreement to commercialise Nextstellis in Vietnam, Philippines
Lupin completes acquisition of two brands from Sanofi in Europe and Canada
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
Lupin announced that its European…
Lupin receives tentative approval from U.S. FDA for Letermovir tablets
The generic equivalent of Prevymis, will be manufactured at Lupin’s Nagpur facility in India
Lupin has announced that it has…
Lupin launches Doxycycline for Injection USP in the United States
Generic equivalent of Vibramycin for Injection, the drug is indicated to reduce the development of drug-resistant bacteria and…
Lupin receives USFDA approval for Midostaurin Capsules
Midostaurin Capsules, 25 mg, are indicated to treat aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated…
Lupin Receives Approval from U.S. FDA for Travoprost Ophthalmic Solution USP
It is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Lupin receives EIR from USFDA for its Aurangabad manufacturing facility
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)